Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more

AI-native drug discovery is here

From 15 years to 5.
From the bench to the browser.

The frontier labs are racing to merge AI with biology. The tools they're scrambling to build, we already ship. Predict binding to ~1 kcal/mol, triage millions of compounds with physics-based docking, and extract every structure from the patent literature — production-ready, today.

  • $50M + $32M capital · ARPA-H contract
  • 100+ scientists biology · chemistry · physics
  • SOC-2 enterprise-ready

Trusted by 4 of the world's 10 largest pharma, and researchers at MIT, Stanford, Caltech, Yale, the Francis Crick Institute, and 30+ leading universities across 6 continents.

What this lets you do

Small molecule drug discovery tools for every stage.

Outcomes first. The underlying capabilities — FEP, docking, structure extraction, ADMET — power every solution. Access them through DO Studio, the Deep Origin API, or Balto AI.

Built for enterprise

Production-grade infrastructure. Validated science.

SOC-2 compliant infrastructure end-to-end encryption · VPC-deployable · your data stays yours
$32M ARPA-H contract in-silico models to replace animal testing
>98% patent extraction accuracy 100x faster than redrawing
100+ scientists biology · chemistry · physics

Up to 90% fewer failed experiments — physics + ML applied before synthesis, validated by published science.

Get started

This is happening, fast. Make sure your team is on it.

Talk to one of our scientists about how the platform fits into your discovery program.